Predicting cancer relapse following lung stereotactic radiotherapy: an external validation study using real-world evidence.

Davey, Angela; Thor, Maria; van Herk, Marcel; Faivre-Finn, Corinne; Rimner, Andreas; Deasy, Joseph O; McWilliam, Alan

Davey, Angela; Thor, Maria; van Herk, Marcel; Faivre-Finn, Corinne; Rimner, Andreas; Deasy, Joseph O; McWilliam, Alan.

Afiliação

Davey A; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Thor M; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
van Herk M; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Faivre-Finn C; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Rimner A; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
Deasy JO; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
McWilliam A; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Front Oncol ; 13: 1156389, 2023.

Article em En | MEDLINE | ID: mdl-37503315

Palavras-chave

NSCLC; biomarker-by-treatment interactions; external validation; image-based data mining; local relapse; personalized medicine; real world data; stereotactic ablative body radiotherapy (SABR)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google